Real-world data on ivosidenib in patients with previously treated isocitrate dehydrogenase 1-mutated intrahepatic cholangiocarcinomas: an early exploratory analysis

M Rimini, V Burgio, L Antonuzzo, L Rimassa… - Targeted Oncology, 2022 - Springer
Background The results of the phase III ClarIDHy trial have led to US FDA approval of
ivosidenib as a therapeutic option for patients with locally advanced or metastatic …

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two …

C Müller, S Franke, T Reisländer, V Keitel… - Case Reports in …, 2024 - karger.com
Introduction: Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring
an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib showed a median …